Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD5 CAR-T Cells in r/r CD5+ T-ALL
NCT06633354Phase 1Recruiting
- Sponsor
- Zhejiang University
- Start
- Oct 2024
- Primary completion
- Oct 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD5 CAR T cells in t-cell acute lymphoblastic leukemia (T-ALL), sponsored by Zhejiang University. Primary endpoints: Dose-limiting toxicity at 28 days and Treatment-emergent adverse events at 2 years. Started Oct 2024; status: recruiting.
02
Drugs
CD5 CAR T cells
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)
Beyond the preview
Go deeper on NCT06633354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06633354.